Cargando…

Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis

Cladribine tablets (CladT) is a highly active oral disease-modifying therapy (DMT) for the management of relapsing multiple sclerosis (RMS). CladT acts as an immune reconstitution therapy, in that two short courses of treatment 1 year apart have been shown to suppress disease activity for a prolonge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clavelou, Pierre, Castelnovo, Giovanni, Pourcher, Valérie, De Sèze, Jerome, Vermersch, Patrick, Ben-Amor, Ali-Frederic, Savarin, Carine, Defer, Gilles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444734/ https://www.ncbi.nlm.nih.gov/pubmed/37382841 http://dx.doi.org/10.1007/s40120-023-00496-3

Ejemplares similares

The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus
por: De Sèze, Jerome, et al.
Publicado: (2022)

Expert opinion on the use of cladribine tablets in clinical practice
por: Sørensen, Per Soelberg, et al.
Publicado: (2020)

Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates
por: Inshasi, Jihad S., et al.
Publicado: (2021)

Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets
por: Yamout, Bassem I, et al.
Publicado: (2022)

Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype
por: Brochet, Bruno, et al.
Publicado: (2022)

The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
por: Hermann, Robert, et al.
Publicado: (2018)

Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice
por: Rieckmann, Peter, et al.
Publicado: (2021)

Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
por: Giovannoni, Gavin, et al.
Publicado: (2022)

Cladribine Tablets and Relapsing–Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know
por: AlJumah, Mohamed, et al.
Publicado: (2020)

Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study
por: Comi, Giancarlo, et al.
Publicado: (2018)

Cladribine Tablets: A Review in Relapsing MS
por: Deeks, Emma D.
Publicado: (2018)

Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
por: Michels, Renée Else, et al.
Publicado: (2019)

Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study
por: Giovannoni, Gavin, et al.
Publicado: (2018)

Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
por: Michels, Renée Else, et al.
Publicado: (2020)

Correction to: Cladribine Tablets: A Review in Relapsing MS
por: Deeks, Emma D.
Publicado: (2019)

Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS
por: de Stefano, Nicola, et al.
Publicado: (2022)

Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets
por: Cortese, Rosa, et al.
Publicado: (2022)

Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain
por: Ginestal, Ricardo, et al.
Publicado: (2023)

Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4
por: Centonze, Diego, et al.
Publicado: (2023)

Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets
por: Moiola, Lucia, et al.
Publicado: (2022)

Effects of cladribine tablets on heart rate, atrio‐ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis
por: Hermann, Robert, et al.
Publicado: (2019)

Cladribine tablets are a cost-effective strategy in high-disease activity relapsing multiple sclerosis patients in Iran
por: Ayati, Nayyereh, et al.
Publicado: (2021)

Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study
por: Montalban, Xavier, et al.
Publicado: (2018)

Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets
por: Gasperini, Claudio, et al.
Publicado: (2010)

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
por: Rammohan, Kottil, et al.
Publicado: (2020)

COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update
por: Jack, Dominic, et al.
Publicado: (2021)

Corrigendum to Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice
Publicado: (2022)

Cladribine Tablets Mode of Action, Learning from the Pandemic: A Narrative Review
por: Carlini, Federico, et al.
Publicado: (2023)

Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies
por: De Stefano, Nicola, et al.
Publicado: (2021)

Multicentre Observational Study of Treatment Satisfaction with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in the Arabian Gulf: The CLUE Study
por: Inshasi, Jihad, et al.
Publicado: (2023)

Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study
por: Brochet, Bruno, et al.
Publicado: (2023)

Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Outcomes of COVID-19 in people with multiple sclerosis treated with cladribine tablets: an update
por: Jack, Dominic, et al.
Publicado: (2021)

Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
por: De Stefano, Nicola, et al.
Publicado: (2017)

Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients
por: Paolicelli, Damiano, et al.
Publicado: (2022)

Evaluation of Patient-Reported Outcomes in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets in the CLAWIR Study: 12-Month Interim Analysis
por: Rau, Daniela, et al.
Publicado: (2023)

Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis
por: Afolabi, Dayo, et al.
Publicado: (2017)

Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety
por: Moser, Tobias, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jv6nkiblmm8pur81hm5hhe08vn